Staphylococcus epidermidis

Chemical pollutants can change your skin bacteria and increase your eczema risk − new research explores how

Retrieved on: 
Tuesday, April 23, 2024
Research, Itch, Dicarboxylic acid, Temperature, Isocyanate, Polyurethane, Gene, Oil, Industrial Revolution, Growth, Atopic dermatitis, Paint, Environment, Risk, Genetics, Lipid, Inflammation, Revolution, Mouse, Child, Bacteria, Detergent, Life, Dermatitis, Staphylococcus aureus, Asthma, Staphylococcus epidermidis, Staphylococcus cohnii, Sensation, EPA, Skin, Plastic, Ceramide, Atmosphere, Lysine, Roseomonas, Staphylococcus, Pain, Air pollution, Wildfire, Vaccine

Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.

Key Points: 
  • Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.
  • Some studies have found rates of eczema in developing nations to be over thirtyfold lower compared with industrialized nations.
  • Scientists know that factors such as diets rich in processed foods as well as exposure to specific detergents and chemicals increase the risk of developing eczema.
  • Living near factories, major roadways or wildfires increase the risk of developing eczema.

There’s something in the air

  • Then we looked at databases from the U.S. Environmental Protection Agency to see which chemicals were most common in those areas.
  • Diisocyanates were first manufactured in the U.S. around 1970 for the production of spandex, nonlatex foam, paint and polyurethane.
  • The manufacture of xylene also increased around that time, alongside an increase in the production of polyester and other materials.
  • After 1975, when all new cars became outfitted with a new technology that converted exhaust gas to less toxic chemicals, isocyanate and xylene both became components of automobile exhaust.
  • How directly exposing mice to these toxins compares to the typical levels of exposure in people is still unclear.

Skin microbiome and pollution

  • Every person is coated with millions of microorganisms that live on the skin, collectively referred to as the skin microbiome.
  • You’ve probably seen moisturizers and other skin products containing ceramides, a group of lipids that play an important role in protecting the skin.
  • To see which toxins could prevent production of the beneficial lipids that prevent eczema, my team and I used skin bacteria as canaries in the coal mine.
  • Lysine helps protect the bacteria from the harms of the toxins but doesn’t provide the health benefits of ceramides.
  • Bacteria that help keep skin healthy could live on any fabric, but, just as with air pollution, the amount of beneficial lipids they made dropped to less than half the levels made when grown on fabrics like cotton.

Addressing pollution’s effects on skin

  • Detectors capable of sensing low levels of isocyanate or xylene could help track pollutants and predict eczema flare-ups across a community.
  • Better detectors can also help researchers identify air filtration systems that can scrub these chemicals from the environment.
  • In the meantime, improving your microbial balance may require avoiding products that limit the growth of healthy skin bacteria.
  • I believe that it may one day allow us to get back to a time when these diseases were uncommon.


Ian Myles receives funding from the Department of Intramural Research at the National Institute of Allergy and Infectious Diseases. He is the author of, and receives royalties for, the book GATTACA Has Fallen: How population genetics failed the populace. Although he is the co-discoverer of Roseomonas mucosa RSM2015 for eczema, he has donated the patent to the public and has no current conflict of interest for its sales.

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Lymphocyte, Dermatology, Patient, Netherton syndrome, IP, LEKTI, Staphylococcus epidermidis, Skin, Disease, Ichthyosis, FDA, Protein, Patent, Netherton

Importantly, the indication addressed by this patent, ichthyosis vulgaris (IV), a chronic, scaly skin disease with no FDA-approved treatment option and affects approximately 1.3 million people in the United States.

Key Points: 
  • Importantly, the indication addressed by this patent, ichthyosis vulgaris (IV), a chronic, scaly skin disease with no FDA-approved treatment option and affects approximately 1.3 million people in the United States.
  • This new patent issuance reinforces the value of our platform for precision dermatology and our commitment to patient populations with no FDA-approved treatment options."
  • Azitra is developing live biotherapeutic product candidates intended to treat ichthyosis vulgaris, a disease caused by missing or abnormal filaggrin levels.
  • Azitra’s growing patent portfolio now has three granted patents in the US with numerous additional applications pending globally to further expand its IP position.

Multiply Labs Releases Preprint Data Showing That Automated and Manual Cell Expansion Processes Are Statistically Equivalent

Retrieved on: 
Friday, January 5, 2024
Research, Pharmaceutical, Robotics, Technology, Other Manufacturing, Science, Engineering, Biotechnology, Other Technology, Manufacturing, Other Science, Health, Multimedia, FDA, Staphylococcus epidermidis, Thermo Fisher Scientific, GMP, Gene, Charles River Laboratories, Multiplication, Therapy, Automation, Cell, UCSF, Skin

This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.

Key Points: 
  • This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.
  • “This data demonstrates that manufacturers can confidently automate their existing processes for cell expansion, without making significant modifications to the process itself, effectively minimizing bioprocess and regulatory risks.
  • In addition to cell count and viability successes, none of the robotic cell expansion samples were contaminated.
  • The research, titled “Development of a robotic cluster for automated and scalable cell therapy manufacturing,” is currently under review.

Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301

Retrieved on: 
Wednesday, November 15, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Pandemic, Peptide, MTB, Lung, Safety, Peptidoglycan, The Union, Serum, PGN, Immunoglobulin G, Risk, Gram-positive bacteria, Epitope, Staphylococcus aureus, ELISA, Infection, Staphylococcus, Staphylococcus epidermidis, Vaccine, Mycobacterium tuberculosis, Bacillus subtilis, Cell wall, AMR, Conference, Streptococcus, Virus, Antibody, Bacilli, Mycobacterium smegmatis, Tuberculosis, Public, TB, ICR, Bacteria, Longhorn, MD

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
  • The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
  • It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.

Genesis MedTech introduces China's first domestic brand of NPMA-approved antibacterial sutures

Retrieved on: 
Tuesday, September 12, 2023
Triclosan, Suture, Staphylococcus, Staphylococcus epidermidis, Infection, MRSA, Gram-negative bacteria, Hospital-acquired infection, Staphylococcus aureus, CDC, MRSE, Patient, Risk, Korea Disease Control and Prevention Agency, Perioperative, National Medical Products Administration, Growth, Methicillin-resistant Staphylococcus aureus, WHO, JAMA Surgery, Lancet, NMPA, Genesis, Dis, World Health Organization, Pharmaceutical industry, Vaccine

The newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent with activity against gram-positive and gram-negative bacteria.

Key Points: 
  • The newly developed antibacterial sutures are coated with triclosan, a broad-spectrum antimicrobial agent with activity against gram-positive and gram-negative bacteria.
  • Alongside the highly anticipated absorbable antibacterial sutures, Genesis MedTech continues to expand its suture product lines with comprehensive offerings.
  • Furthermore, its barbed absorbable sutures with black needle, non-absorbable surgical polypropylene sutures, and controlled-release needle sutures have been widely used in thousands of hospitals nationwide.
  • Warren Wang, Chairman and CEO of Genesis MedTech Group, expressed his excitement stating, "We are thrilled to achieve this significant milestone as the first domestic brand in China to develop antibacterial sutures.

Skin, mouth, lungs ... it's not just your gut that has a microbiome

Retrieved on: 
Friday, July 21, 2023
Extrapyramidal system, COPD, Asthma, Obesity, Mouth, Depression, Urinary tract infection, Genetics, Atmosphere, Inflammatory Bowel Diseases, Digestion, Dermatitis, Anxiety, Infection, Staphylococcus epidermidis, Sugar, Skin, Type 2 diabetes, Bacterial vaginosis, Nutrient, Respiratory system, Acne, Candidiasis, Fungus, Psoriasis, Chronic obstructive pulmonary disease, Nose, Membrane, Nutritional science, Sinusitis, Rhinitis, Metabolism, Collection, Archaea, Risk, Immune system, Oral hygiene, Vitamin K, Growth, Bacteria, Health, Air pollution, Virus, Probiotic, Environment, New Scientist, Pneumonia, Antibiotics, Vaccine, Pharmaceutical industry, Birth control, Gum arabic

A lot has been written and said about the gut microbiome – the community of bacteria, viruses, fungi and archaea that lives in our intestines. But the gut is not the only place that has a microbiome. The mouth, nose, skin, lungs and genitals have microbiomes of their own. And they all play an important role in our health. Here is a brief introduction to each one. Oral microbiome Arguably, this was the first microbiome discovered.

Key Points: 


A lot has been written and said about the gut microbiome – the community of bacteria, viruses, fungi and archaea that lives in our intestines. But the gut is not the only place that has a microbiome. The mouth, nose, skin, lungs and genitals have microbiomes of their own. And they all play an important role in our health. Here is a brief introduction to each one.

Oral microbiome

    • Arguably, this was the first microbiome discovered.
    • As with all microbiomes, the oral microbiome competes with harmful bacteria for resources and space.
    • Good oral hygiene and a healthy diet can ensure that good microbes prevail.

Nasal microbiome

    • Moving north, we find the nasal microbiome, which helps to filter and trap particles from the air we breathe.
    • While the nasal microbiome has over a hundred strains of bacteria, only two to ten species make up 90% of the microbiome.
    • However, imbalances in the nasal microbiome can occur as a result of environmental exposures (such as air pollution), genetics or problems with our immune system.

Skin microbiome

    • The skin microbiome includes bacteria, fungi and viruses.
    • Imbalances in the skin microbiome have been associated with skin conditions like acne, eczema, psoriasis and dermatitis.

Lung microbiome

    • The lung microbiome is not as diverse as the other biomes, mainly consisting of bacteria.
    • Disruptions in the lung microbiome can make us more susceptible to infections and respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and pneumonia.

Genital microbiome

    • Heading further south, we have the vaginal microbiome in females and the penile microbiome in males.
    • The penile microbiome in males also contributes to genital health, although it has been less extensively studied.

Gut microbiome

    • The gut microbiome is essential for digestion, metabolism and developing our immune system.
    • Imbalances in the gut microbiome have been linked to conditions like inflammatory bowel diseases, obesity, type 2 diabetes, and mental health disorders, such as depression and anxiety.
    • There are various ways to keep the gut microbiome healthy or rebalance it when it gets out of whack.
    • Disruptions in the gut microbiome can influence our immune system and affect other biomes.

Photodisinfection Found to Eradicate Biofilms Associated With Periprosthetic Joint Infections

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, PDT, Infection, ESKAPE, Photosensitizer, Teaching hospital, AIM, Staphylococcus epidermidis, Internal medicine, Staphylococcus, Staphylococcus aureus, Biofilm, Escherichia coli, University Hospital of Zürich, Disease, Mortality, Research, Antibiotic, Pharmaceutical industry, Cutibacterium

A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").

Key Points: 
  • A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").
  • The results of this study suggest that photodisinfection could be used as an effective treatment method for PJIs, replacing current, more invasive approaches and potentially shortening antibiotic treatment.
  • This would not only improve patients’ quality of life, but also reduce morbidity, mortality, antibiotic resistance, and the high healthcare costs associated with treating these infections.
  • The in vitro study, conducted by a research team from University Hospital Zurich, found that photodisinfection achieved 100% kill of the key pathogens in biofilms associated with PJIs.

Seoul Viosys: Through Air Purifier and Air Sterilizer Filters, Bacterial Growth and Leakage Occur

Retrieved on: 
Thursday, December 29, 2022
Semiconductor, Health, Medical Devices, Infectious Diseases, Technology, COVID-19, Hardware, Infection, KOSDAQ, Survival, Prof Bioresearch, Research, Federal Food, Drug, and Cosmetic Act, Staphylococcus epidermidis, Virus, Multimedia, Cosmetics, Donaldson Company, Diarrhea, Vomiting, HEPA, Genetically modified bacteria, Pain scale, Degenerative disease, Filter, Atmosphere, UV, Bacillus atrophaeus, COVID-19, KRW, Severe acute respiratory syndrome coronavirus 2, Sterilization, SOHO, Vaccine, Wine

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market.

Key Points: 
  • Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market.
  • The test confirms that bacterial growth and its leakage occur through the filters.
  • The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.
  • Air purifiers sold in the market were randomly selected and the filter contamination level was checked.

Datasea Unveils National Hailijia Air Sterilizer Product Campaign

Retrieved on: 
Thursday, December 8, 2022
Cloud, Wuhan Institute of Virology, Life, RNA, Airport, School, Staphylococcus epidermidis, Communication, Coronavirus, Disinfectant, Big data, Science, Marketing, Hospital, Escherichia coli, Digital technology, Vibration, Beijing Science and Technology University Gymnasium, TUV, Health, COVID-19, Transport, Atmosphere, Certification, UL, Research, Investment, MIIT, Patent, Sterilization, Communications and Information Technology Commission (Saudi Arabia), Attention, City, Agriculture, Cloud computing, Medical device, Virology

Today, the Company announced that it has unveiled the national Hailijia air sterilizer product campaign with an online event and offline product showcases in various cities in China, including Beijing, Shenzhen, Tianjin, Hangzhou and Shanghai.

Key Points: 
  • Today, the Company announced that it has unveiled the national Hailijia air sterilizer product campaign with an online event and offline product showcases in various cities in China, including Beijing, Shenzhen, Tianjin, Hangzhou and Shanghai.
  • During the product campaign, Datasea has entered into eight marketing and distribution agreements in order to expand the business and reach to customers and sell certain Hailijia air sterilizers and purifiers in China.
  • Hailijia air sterilizers have fifteen software copyrights in China, three patents in China and eight patent applications are pending in China.
  • Going forward, Datasea will continue to increase research and development investments in the field of acoustic intelligence and accelerate product upgrades.

New Research Confirms HealthWay's Air Purifiers are 99.99% Effective in Killing Common Bacteria and Viruses

Retrieved on: 
Tuesday, December 6, 2022
Travel, Laboratory, ILPA, Super V, Virus, New York State Department of Health, Methicillin-resistant Staphylococcus aureus, Socially responsible investing, Rockefeller Group, Dagenham Heathway tube station, Environment, Commercial, School, Bacteria, DFS, Atmosphere of Earth, United Nations Principles of Medical Ethics, Research, JPMorgan Chase, HVAC, Belcan, Methicillin, MS2, Staphylococcus aureus, Rockefeller Group Business Center, Marketing, Staphylococcus epidermidis, RNA, MRSA, Heating, ventilation, and air conditioning, The Ritz-Carlton Hotel Company, United Airlines

PULASKI, N.Y., Dec. 6, 2022 /PRNewswire/ -- HealthWay (or the "Company"), a global leader in air purification solutions for both commercial and residential settings, today released laboratory results showing the Company's high volume air purifiers capture and kill both bacteria and viruses with over 99.99% efficiency. Testing on a variety of pathogens conducted by two separate third-party laboratories this fall corroborated the results.   

Key Points: 
  • With the log 4 reduction rate demonstrated by these results, HealthWay customers can be confident that their air quality meets the highest standards for a healthy environment."
  • The Company's in-line Super V air purifiers are installed in HVAC ducts, typically in commercial settings or for whole-home residential installations.
  • "This new data further substantiates HeathWay's findings that our products are effective in removing airborne bacteria and viruses.
  • Whether the setting is a school, office or home, there is a cost-effective HealthWay indoor air quality solution available."